CAM cancer therapies
This article was originally published in The Tan Sheet
NCCAM will spend 12% of FY 2002 budget (roughly $12.6 mil.) on cancer research projects, according to figures released at Cancer Advisory Panel for Complementary & Alternative Medicine meeting in Bethesda, Md. Feb. 25. Also, CAPCAM Executive Secretary Richard Nahin, PhD, will be replaced by NCCAM Program Officer Mary Ann Richardson, and Chairman Michael Hawkins, MD, Washington (D.C.) Hospital Center, will leave the panel upon expiration of his term March 31. Nahin is leaving his position as NCCAM's extramural research director to become the center's senior advisor on scientific coordination...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.